Biomea Fusion, Inc.

Equities

BMEA

US09077A1060

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 06/07/2024 am IST			5-day change	1st Jan Change
4.23 ^USD	-2.76%		-6.00%	-70.87%

24/06	Biomea Fusion, Inc.(NasdaqGS:BMEA) dropped from S&P Biotechnology Select Industry Index	CI
11/06	Biomea Fusion Downgraded to Hold at Truist Securities With No Price Target Following Clinical Hold Placed by FDA Last Week	MT

Biomea Fusion Moves into New Headquarters and Expands R&D Facility

January 05, 2022 at 12:00 am IST

Biomea Fusion, Inc. announced that it has moved into new headquarters in Redwood City, at 900 Middlefield Road. Located in the heart of Redwood City, within the Crossing 900 development, the new headquarters is immediately adjacent to the Redwood City Caltrain Station. The space offers a vibrant, work environment of more than 27,000 sq.

ft. and will support the company's anticipated growth in 2022 and beyond. Biomea also announced it has initiated the second phase of the buildout of its R&D Innovation Center, which is anticipated to be completed in the second half of 2022.

The expanded 18,000 sq. ft. R&D Innovation Center will support additional biology and medicinal chemistry as well as drug metabolism, pharmacokinetics, and process chemistry research for all three programs in the company's pipeline.

Latest news about Biomea Fusion, Inc.

Biomea Fusion, Inc.(NasdaqGS:BMEA) dropped from S&P Biotechnology Select Industry Index	24/06	CI
Biomea Fusion Downgraded to Hold at Truist Securities With No Price Target Following Clinical Hold Placed by FDA Last Week	11/06	MT
Sector Update: Health Care Stocks Higher Late Afternoon	08/06	MT
Top Midday Decliners	07/06	MT
Piper Sandler Adjusts Price Target on Biomea Fusion to $10 From $45, Maintains Overweight Rating	07/06	MT
Scotiabank Cuts Price Target on Biomea Fusion to $21 From $41, Maintains Sector Outperform Rating	07/06	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	07/06	MT
Jobs Growth Tops Forecasts as US Equity Futures Post Narrow Losses Pre-Bell	07/06	MT
Top Premarket Decliners	07/06	MT
Barclays Downgrades Biomea Fusion to Equalweight From Overweight, Adjusts Price Target to $5 From $30	07/06	MT
Biomea Reports Diabetes Drug Candidate Placed on Clinical Hold; Shares Plummet Premarket	07/06	MT
Biomea Fusion Down 61% on Clinical Hold for Diabetes Drug	07/06	DJ
Biomea Reports Diabetes Drug Candidate Placed on Clinical Hold	07/06	MT
U.S. FDA places hold on Biomea's diabetes trial	07/06	RE
Biomea Fusion, Inc. Announces BMF-219 in Diabetes Placed on Clinical Hold	07/06	CI
Biomea Fusion Completes Enrollment of First 3 Dose Expansion Arms of Diabetes Trial	30/05	MT
Biomea Fusion, Inc. Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes	30/05	CI
Oppenheimer Adjusts Biomea Fusion Price Target to $60 From $70, Maintains Outperform Rating	30/05	MT
Biomea Fusion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05	CI
North American Morning Briefing : Powell Awaited -2-	03/04	DJ
Biomea Fusion Shares Decline Following JPMorgan Downgrade	03/04	MT
JPMorgan Downgrades Biomea Fusion to Neutral From Overweight, Adjusts Price Target to $14 From $51	02/04	MT
Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)	01/04	CI
Biomea Fusion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
North American Morning Briefing : Tech in Focus on -2-	25/03	DJ

Chart Biomea Fusion, Inc.

Duration

Period

More charts

Company Profile

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).

Sector

Biotechnology & Medical Research

Calendar

29/07/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.23 USD

Average target price

24.43 USD

Spread / Average Target

+477.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOMEA FUSION, INC.	-70.87%	15Cr
MODERNA, INC.	+18.97%	4.53TCr
LONZA GROUP AG	+41.98%	4.04TCr
IQVIA HOLDINGS INC.	-10.06%	3.79TCr
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	3.18TCr
CELLTRION, INC.	-7.79%	2.77TCr
ICON PUBLIC LIMITED COMPANY	+13.32%	2.65TCr
UNITED THERAPEUTICS CORPORATION	+43.05%	1.4TCr
MEDPACE HOLDINGS, INC.	+31.28%	1.24TCr
BIO-TECHNE CORPORATION	-7.41%	1.13TCr

Other Biotechnology & Medical Research